Erlocip Tablets (Erlotinib) 100mg & 150mg | Lung Cancer Treatment

Erlocip Tablets (Erlotinib) 100mg & 150mg

What is Erlocip?

Erlocip Tablets contain Erlotinib, an oral targeted therapy used to treat certain types of non-small cell lung cancer (NSCLC) and advanced pancreatic cancer. Erlotinib belongs to a class of medicines called EGFR (Epidermal Growth Factor Receptor) inhibitors, which help slow or stop the growth of cancer cells by blocking signals responsible for tumor growth.

Erlocip is available in 100mg and 150mg strengths and should only be taken under the supervision of a qualified oncologist.

Uses of Erlocip Tablets

Erlocip is prescribed for:

EGFR mutation-positive non-small cell lung cancer (NSCLC)

Advanced or metastatic NSCLC

Maintenance treatment for eligible lung cancer patients

Advanced pancreatic cancer in combination with Gemcitabine

Your doctor will determine whether Erlocip is the right treatment based on your cancer type and medical condition.

How Erlocip Works

Erlotinib blocks the EGFR protein, which plays an important role in the growth and spread of cancer cells. By inhibiting this receptor, Erlocip helps:

Slow cancer cell growth

Delay tumor progression

Reduce the spread of cancer cells

Improve progression-free survival in suitable patients

Available Strengths

Erlocip 100mg

Typically prescribed for:

Pancreatic cancer with Gemcitabine

Dose adjustments due to side effects

Individualized treatment plans

Erlocip 150mg

Commonly used for:

EGFR-positive metastatic non-small cell lung cancer

First-line targeted therapy

Maintenance therapy

Always take the strength prescribed by your doctor.

Dosage & Administration

Take once daily on an empty stomach (at least 1 hour before or 2 hours after meals).

Swallow the tablet whole with water.

Take it at the same time each day.

Do not crush or chew the tablet.

If you miss a dose, follow your doctor's advice. Do not double the dose.

Benefits of Erlocip

Targeted treatment for EGFR-positive cancers

Convenient oral tablet

Helps slow disease progression

May improve treatment outcomes

Often better tolerated than traditional chemotherapy

Possible Side Effects

Common side effects include:

Skin rash

Diarrhea

Dry skin

Fatigue

Loss of appetite

Mouth sores

Nausea

Seek immediate medical attention if you experience severe breathing problems, persistent diarrhea, serious skin reactions, eye pain, or signs of liver problems.

Precautions

Before taking Erlocip, inform your doctor if you have:

Liver or kidney disease

Lung disorders

Eye problems

A history of smoking

Pregnancy or breastfeeding

Smoking can reduce the effectiveness of Erlotinib, so quitting smoking is recommended during treatment.

Drug Interactions

Tell your healthcare provider about all medicines you take, including:

Antacids and acid-reducing medicines

Blood thinners

Antibiotics

Antifungal medicines

Herbal supplements

Vitamins

Some medicines may affect how Erlocip works.

Storage

Store below 30°C.

Keep away from moisture and direct sunlight.

Keep out of reach of children.

Frequently Asked Questions (FAQs)

1. What is Erlocip Tablet used for?

Erlocip is used to treat EGFR-positive non-small cell lung cancer and advanced pancreatic cancer (with Gemcitabine).

2. Is Erlocip chemotherapy?

No. Erlocip is a targeted therapy that specifically blocks EGFR proteins involved in cancer growth.

3. What is the difference between Erlocip 100mg and 150mg?

The difference is the dosage strength. Your doctor will prescribe the appropriate dose based on your condition and treatment plan.

4. How should Erlocip be taken?

Take it once daily on an empty stomach, at least one hour before or two hours after meals.

5. What are the common side effects?

Common side effects include skin rash, diarrhea, fatigue, nausea, dry skin, and loss of appetite.

6. Can smokers take Erlocip?

Smoking may reduce the effectiveness of Erlotinib. Patients are advised to quit smoking during treatment.

7. How long should Erlocip be taken?

Treatment usually continues until disease progression, unacceptable side effects, or as advised by your oncologist.

8. Is Erlocip safe during pregnancy?

No. Erlocip may harm an unborn baby. Effective contraception should be used during treatment and as recommended by your doctor afterward.

Why Choose Erlocip?

Erlocip (Erlotinib) is a proven targeted therapy for eligible patients with EGFR-positive non-small cell lung cancer and advanced pancreatic cancer. When used under medical supervision, it can help slow disease progression and improve treatment outcomes.

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult your oncologist before starting or stopping Erlocip treatment.